Clinical Trials
57
Active:2
Completed:11
Trial Phases
5 Phases
Early Phase 1:4
Phase 1:8
Phase 2:7
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
Not Applicable
20 (44.4%)Phase 1
8 (17.8%)Phase 2
7 (15.6%)Phase 4
6 (13.3%)Early Phase 1
4 (8.9%)Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
Not Applicable
Recruiting
- Conditions
- CLLCAR-T Cell TherapySLL
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Target Recruit Count
- 50
- Registration Number
- NCT07120633
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
The Effect of Exercise on Blood Pressure Variability on Peritoneal Dialysis Patients
Not Applicable
Completed
- Conditions
- Peritoneal Dialysis (PD)CKD (Chronic Kidney Disease) Stage 5D
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Target Recruit Count
- 55
- Registration Number
- NCT07098923
- Locations
- 🇨🇳
The affiliated hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
Not Applicable
Active, not recruiting
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Target Recruit Count
- 150
- Registration Number
- NCT07098897
- Locations
- 🇨🇳
The First Affiliated hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Not Applicable
Recruiting
- Conditions
- Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma Refractory
- Interventions
- Drug: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Target Recruit Count
- 40
- Registration Number
- NCT07058103
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- Multiple Myeloma (MM)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Chimeric Antigen Receptor T-cell
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-07-02
- Target Recruit Count
- 20
- Registration Number
- NCT07034755
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
No news found